

SCHWERPUNKT: LEBER- UND PANKREASKARZINOM

Systemtherapie für das Hepatozelluläre Karzinom – Update 2020 (S. 16–19)

M. M.Kirstein

1. El-Serag HB. Hepatocellular carcinoma. *N Engl J Med* 2011; 365: 1118–1127
2. Ferlay J et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015; 136: E359–386
3. Llovet JM et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. *J Hepatol* 1999 Jan; 29(1): 62–7
4. Malek NP et al.. The diagnosis and treatment of hepatocellular carcinoma. *Dtsch Arztebl Int* 2014; 111: 101–106
5. Vogel A et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018; 29 (Supplement 4): iv238–iv255
6. Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. *N Engl J Med* 2008; 359: 378–390
7. Okamoto K et al. Distinct binding mode of multikinase inhibitor lenvatinib revealed by biochemical characterization. *ACS Med Chem Lett* 2015; 6: 89–94
8. Kudo M et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. *Lancet* 2018; 391; 10126: 1163–1173
9. Finn RS et al. KEYNOTE-240 investigators. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial. *J Clin Oncol* 2020 Jan 20; 38(3): 193–202
10. Yau T et al. CheckMate 459: A Randomized, Multi-center Phase III Study of Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma. *Ann Oncol* 2019; 30 (suppl_5): v851–v934
11. Cheng AL et al. IMbrave150: Efficacy and safety results from a phase III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). *Ann Oncol* 2019; 30 (suppl_9)12. Yau T et al. Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. *J Clin Oncol* 37, 2019 (suppl; #abstr 4012)
13. Ikeda M et al. A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). *J Clin Oncol* 2018; 36, no. 15_suppl (May 20 2018) 4076–4076
14. Bruix J et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2017; 389: 56–66
15. Abou-Alfa GK et al. Cabozantinib (C) versus placebo (P) in patients (pts) with advanced hepatocellular carcinoma (HCC) who have received prior sorafenib: Results from the randomized phase III CELESTIAL trial. *J Clin Oncol* 2018; 36, no. 4_suppl (February 1 2018) 207–207
16. Zhu AX et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α -fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet Oncol* 2019; 20 (2): 282–296
17. Finn RS et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial. *J Hepatol* 2018 Aug; 69(2): 353–358

18. Bruix J et al. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. *Lancet Oncol* 2015 Oct; 16(13): 1344–54
 19. Lencioni R et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. *J Hepatol* 2016 May; 64(5): 1090–1098
-

Lokoregionäre Therapien für das Hepatozelluläre Karzinom: RFA, TACE, SIRT (S. 20–24)

J. M. Theysohn

1. Grieco A et al. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. *Gut* 2005; 54(3): 411–418
2. Sorensen JB et al. Performance status assessment in cancer patients. An inter-observer variability study. *Br J Cancer* 1993; 67(4): 773–775
3. Mazzaferro V et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. *N Eng J Med* 1996; 334(11): 693–699
4. Sangro B et al. Radioembolization for hepatocellular carcinoma. *J Hepatol* 2012; 56(2): 464–473
5. Salem R et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. *Eur J Nucl Med Mol Imaging* 2019; 46(8): 1695–1704
6. Garin E et al. Major impact of personalized dosimetry using 90Y loaded glass microspheres SIRT in HCC: Final overall survival analysis of a multicenter randomized phase II study (DOSISPHERE-01). *J Clin Oncol* 2020; 38(4_suppl): 516–516
7. Huang J et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. *Ann Surg* 2010; 252(6): 903–912
8. Zhou Y et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. *BMC gastroenterol* 2010; 10: 78
9. Livraghi T et al.. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. *Radiology* 2003; 226(2): 441–451
10. Liu Z et al. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. *Surg Laparosc Endosc Percutan Tech* 2010; 20(3): 130–140
11. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. *Hepatology (Baltimore, Md)* 2011; 53(3): 1020–1022
12. Livraghi T et al. Percutaneous ethanol injection in the treatment of hepatocellular carcinoma in cirrhosis. A study on 207 patients. *Cancer* 1992; 69(4): 925–929
13. Chen HW et al. Ultrasound-guided percutaneous cryotherapy of hepatocellular carcinoma. *Int j Surg (London, England)* 2011; 9(2): 188–191
14. Lubner MG et al. Microwave tumor ablation: mechanism of action, clinical results, and devices. *J Vasc Interv Radiol* 2010; 21(8 Suppl): S192–203

15. Liang P, Wang Y. Microwave ablation of hepatocellular carcinoma. *Oncol* 2007; 72 Suppl 1: 124–131
16. He N et al. Microwave ablation: An experimental comparative study on internally cooled antenna versus non-internally cooled antenna in liver models. *Acad Radiol* 2010; 17(7): 894–899
17. Fan ST et al. Continuous improvement of survival outcomes of resection of hepatocellular carcinoma: a 20-year experience. *Ann Surg* 2011; 253(4): 745–758
18. Shi J et al. Comparison of microwave ablation and surgical resection for treatment of hepatocellular carcinomas conforming to Milan criteria. *J Gastroenterol Hepatol* 2014; 29(7): 1500–1507
19. Zhang L et al. Therapeutic efficacy of percutaneous radiofrequency ablation versus microwave ablation for hepatocellular carcinoma. *PLoS one* 2013; 8(10): e76119
20. Potretzke TA et al. Microwave versus Radiofrequency Ablation Treatment for Hepatocellular Carcinoma: A Comparison of Efficacy at a Single Center. *J Vasc Interv Radiol* 2016; 27(5): 631–638
21. Savic LJ et al. Irreversible Electroporation in Interventional Oncology: Where We Stand and Where We Go. *RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin* 2016; 188(8): 735–745
22. Cannon R et al. Safety and early efficacy of irreversible electroporation for hepatic tumors in proximity to vital structures. *J Surg Oncol* 2013; 107(5): 544–549
23. Cheung W et al. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience and review of safety and outcomes. *Technol Cancer Res Treat* 2013; 12(3): 233–241
24. Thomson KR et al. Investigation of the safety of irreversible electroporation in humans. *J Vasc Interv Radiol* 2011; 22(5): 611–621
25. Diana M et al. High intensity focused ultrasound (HIFU) applied to hepato-bilio-pancreatic and the digestive system-current state of the art and future perspectives. *Hepatobiliary Surg Nutr* 2016; 5(4): 329–344
26. Li C et al. Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma. *Eur J Cancer (Oxford, England : 1990)* 2010; 46(13): 2513–2521
27. Di Costanzo GG et al. Laser ablation for small hepatocellular carcinoma: State of the art and future perspectives. *World J Hepatol* 2014; 6(10): 704–715
28. Ferrari FS et al. Treatment of small HCC through radiofrequency ablation and laser ablation. Comparison of techniques and long-term results. *Radiol Med* 2007; 112(3): 377–393
29. Chuang VP, Wallace S. Hepatic artery embolization in the treatment of hepatic neoplasms. *Radiol* 1981; 140(1): 51–58
30. Obi S et al. Current Status of Hepatic Arterial Infusion Chemotherapy. *Liver cancer* 2015; 4(3): 188–199
31. Ueshima K et al. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma. *Oncol* 2010; 78 Suppl 1: 148–153

32. Malagari K et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 2010; 33(3): 541–551
33. Brown KT et al. Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone. *J Clin Oncol* 2016; 34(17): 2046–2053
34. Camma C et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. *Radiol* 2002; 224(1): 47–54
35. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. *Hepatology (Baltimore, Md)* 2003; 37(2): 429–442
36. Llovet JM et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. *Lancet (London, England)* 2002; 359(9319): 1734–1739
37. Anderson JH et al. Experimental transcatheter intraarterial infusion-occlusion chemotherapy. *Invest Radiol* 1981; 16(6): 496–500
38. Deschamps F et al. Parameters for Stable Water-in-Oil Lipiodol Emulsion for Liver Trans-Arterial Chemo-Embolization. *Cardiovasc Intervent Radiol* 2017; 40(12): 1927–1932
39. Nakamura H et al. Transcatheter oily chemoembolization of hepatocellular carcinoma. *Radiol* 1989; 170(3 Pt 1): 783–786
40. Sacco Ret al. Transarterial chemoembolization for the treatment of hepatocellular carcinoma: a review. *J Hepatocell Carcinoma* 2017; 4: 105–110
41. Lewis AL et al. DC bead: in vitro characterization of a drug-delivery device for transarterial chemoembolization. *J Vasc Intervent Radiol* 2006; 17(2 Pt 1): 335–342
42. Golfieri R et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. *Br J Cancer* 2014; 111(2): 255–264
43. Lammer J et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. *Cardiovasc Intervent Radiol* 2010; 33(1): 41–52
44. Gross A, Albrecht T. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy. *Cardiovasc Intervent Radiol* 2020; 43(3): 402–410
45. Morgan B et al. Intra-arterial brachytherapy of hepatic malignancies: watch the flow. *Nat Rev Clin Oncol* 2011; 8(2): 115–120
46. Lewandowski RJ et al. Radioembolization with 90Y microspheres: angiographic and technical considerations. *Cardiovasc Intervent Radiol* 2007; 30(4): 571–592
47. Salem R et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. *Gastroenterol* 2010; 138(1): 52–64
48. Zhang Y et al. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: A meta-analysis. *Biosci Trends* 2015; 9(5): 289–298

49. Chow PKH et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. *J Clin Oncol* 2018; 36(19): 1913–1921
50. Vilgrain V et al. SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma. *J Hepatol* 2017; 66(1): S85–S86
51. Morimoto M et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. *Cancer* 2010; 116(23): 5452–5460
52. Lencioni R et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. *J Hepatol* 2008; 49(2): 217–222
53. Bruix J et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial. *J Hepatol* 2012; 57(4): 821–829
54. Llovet JM et al. Sorafenib in advanced hepatocellular carcinoma. *N Eng J Med* 2008; 359(4): 378–390
55. Mahvash A et al. Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma. *J Hepatocell Carcinoma* 2016; 3: 1–7
56. Park JW et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. *J Hepatol* 2012; 56(6): 1336–1342
57. Pawlik TM et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. *J Clin Oncol* 2011; 29(30): 3960–3967
58. Dendy MS et al. Locoregional Therapy, Immunotherapy and the Combination in Hepatocellular Carcinoma: Future Directions. *Liver Cancer* 2019; 8(5): 326–340
59. Demaria S et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. *Int J Radiat Oncol Biol Phys* 2004; 58(3): 862–870
60. Hansler J et al. Activation and dramatically increased cytolytic activity of tumor specific T lymphocytes after radio-frequency ablation in patients with hepatocellular carcinoma and colorectal liver metastases. *World J Gastroenterol* 2006; 12(23): 3716–3721
61. Mizukoshi E et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. *Hepatol* 2013; 57(4): 1448–1457
62. Horiguchi S et al. Primary chemically induced tumors induce profound immunosuppression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. *Cancer Res* 1999; 59(12): 2950–2956
63. Liao J et al. Effect of transcatheter arterial chemoembolization on cellular immune function and regulatory T cells in patients with hepatocellular carcinoma. *Mol Med Rep* 2015; 12(4): 6065–6071
64. Chew V et al. Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma. *Gut* 2019; 68(2): 335–346
65. Slovak R et al. Immuno-thermal ablations - boosting the anticancer immune response. *J Immunother Cancer* 2017; 5(1): 78

66. Kim K et al. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells. *Proc Natl Acad Sci U S A* 2014; 111(32): 11774–11779
 67. Duffy AG et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. *J Hepatol* 2017; 66(3): 545–551
-

UPDATE:

Was bringen Änderungen moderner Lifestylefaktoren in der Primärprävention des Mammakarzinoms? (S.49–54)

J. Stubert, B. Gerber, M. Dieterich

1. Ferlay J et al. Global cancer observatory: Cancer today. Lyon, france: International agency for research on cancer. Available from: <https://gco.iarc.fr/today>, accessed [22 Januar 2020]. 2018
2. Ziegler RG et al. Migration patterns and breast cancer risk in asian-american women. *J Natl Cancer Inst* 1993; 85: 1819–1827
3. World cancer research fund/american institute for cancer research. Continuous update project expert report 2018. Judging the evidence. Available at dietandcancerreport.org
4. Maas P et al. Breast cancer risk from modifiable and nonmodifiable risk factors among white women in the united states. *JAMA Oncol* 2016; 2: 1295–1302
5. van Gemert WA et al. The proportion of postmenopausal breast cancer cases in the netherlands attributable to lifestyle-related risk factors. *Breast Cancer Res Treat* 2015; 152: 155–162
6. Behrens G et al. Cancers due to excess weight, low physical activity, and unhealthy diet. *Dtsch Arztebl Int* 2018; 115: 578–585
7. Scoccianti C et al. Female breast cancer and alcohol consumption: A review of the literature. *Am J Prev Med* 2014; 46: S16–25
8. Smith-Warner SA et al. Alcohol and breast cancer in women: A pooled analysis of cohort studies. *JAMA* 1998; 279: 535–540
9. Key J et al. Meta-analysis of studies of alcohol and breast cancer with consideration of the methodological issues. *Cancer Causes Control* 2006; 17: 759–770
10. Di Castelnuovo A et al. Alcohol dosing and total mortality in men and women: An updated meta-analysis of 34 prospective studies. *Arch Intern Med* 2006; 166: 2437–2445
11. Ronksley PE et al. Association of alcohol consumption with selected cardiovascular disease outcomes: A systematic review and meta-analysis. *BMJ* 2011; 342: d671
12. Gaudet MM et al. Active smoking and breast cancer risk: Original cohort data and meta-analysis. *J Natl Cancer Inst* 2013; 105: 515–525
13. Catsburg C et al. Active cigarette smoking and risk of breast cancer. *Int J Cancer* 2015; 136: 2204–2209
14. World: World cancer research fund/american institute for cancer research. Continuous update project expert report 2018. Diet, nutrition, physical activity and breast cancer. Available at dietandcancerreport.org
15. Iyengar NM et al. Association of body fat and risk of breast cancer in postmenopausal women with normal body mass index: A secondary analysis of a randomized clinical trial and observational study. *JAMA Oncol* 2019; 5: 155–163
16. Alexander DD et al. A review and meta-analysis of red and processed meat consumption and breast cancer. *Nutr Res Rev* 2010; 23: 349–365
17. Anderson JJ et al. Red and processed meat consumption and breast cancer: Uk biobank cohort study and meta-analysis. *Eur J Cancer* 2018; 90: 73–82
18. Wu J et al. Dietary protein sources and incidence of breast cancer: A dose-response meta-analysis of prospective studies. *Nutrients* 2016; 8

19. Zang J et al. The association between dairy intake and breast cancer in western and asian populations: A systematic review and meta-analysis. *J Breast Cancer* 2015; 18: 313–322
20. Pala V et al. Meat, eggs, dairy products, and risk of breast cancer in the european prospective investigation into cancer and nutrition (epic) cohort. *Am J Clin Nutr* 2009; 90: 602–612
21. Schulz M et al. Identification of a dietary pattern characterized by high-fat food choices associated with increased risk of breast cancer: The european prospective investigation into cancer and nutrition (epic)-potsdam study. *Br J Nutr* 2008; 100: 942–946
22. Alexander DD et al. Summary and meta-analysis of prospective studies of animal fat intake and breast cancer. *Nutr Res Rev* 2010; 23: 169–179
23. Chazelas E et al. Sugary drink consumption and risk of cancer: Results from nutrinet-sante prospective cohort. *BMJ* 2019; 366: l2408
24. Aune D et al. Dietary fiber and breast cancer risk: A systematic review and meta-analysis of prospective studies. *Ann Oncol* 2012; 23: 1394–1402
25. Schwingshackl L et al. Adherence to mediterranean diet and risk of cancer: An updated systematic review and meta-analysis. *Nutrients* 2017; 9
26. van den Brandt PA, Schulpen M. Mediterranean diet adherence and risk of postmenopausal breast cancer: Results of a cohort study and meta-analysis. *Int J Cancer* 2017; 140: 2220–2231
27. Toledo E et al. Mediterranean diet and invasive breast cancer risk among women at high cardiovascular risk in the predimed trial: A randomized clinical trial. *JAMA Intern Med* 2015; 175: 1752–1760
28. Pizot C et al. Physical activity, hormone replacement therapy and breast cancer risk: A meta-analysis of prospective studies. *Eur J Cancer* 2016; 52: 138–154
29. Wu Y et al. Physical activity and risk of breast cancer: A meta-analysis of prospective studies. *Breast Cancer Res Treat* 2013; 137: 869–882
30. Wu Y, Zhang D. Meta-analyses of etiologic studies should account for the underlying biologic mechanisms. *Breast Cancer Res Treat* 2015; 149: 801–803
31. Schmidt S, Monk JM, Robinson LE, Mourtzakis M. The integrative role of leptin, oestrogen and the insulin family in obesity-associated breast cancer: Potential effects of exercise. *Obes Rev* 2015; 16: 473–487
32. Friedenreich CM, Neilson HK, Wang Q, Stanczyk FZ, Yasui Y, Duha A, et al. Effects of exercise dose on endogenous estrogens in postmenopausal women: A randomized trial. *Endocr Relat Cancer* 2015; 22: 863–876
33. de Boer MC, Worner EA, Verlaan D, van Leeuwen PAM. The mechanisms and effects of physical activity on breast cancer. *Clin Breast Cancer* 2017; 17: 272–278
34. Friedenreich CM, Neilson HK, O'Reilly R, Duha A, Yasui Y, Morielli AR, et al. Effects of a high vs moderate volume of aerobic exercise on adiposity outcomes in postmenopausal women: A randomized clinical trial. *JAMA Oncol* 2015; 1: 766–776
35. McTiernan A, Wu L, Chen C, Chlebowski R, Mossavar-Rahmani Y, Modugno F, et al. Relation of bmi and physical activity to sex hormones in postmenopausal women. *Obesity (Silver Spring)* 2006; 14: 1662–1677
36. Duijts SF, Zeegers MP, Borne BV. The association between stressful life events and breast cancer risk: A meta-analysis. *Int J Cancer* 2003; 107: 1023–1029
37. Lin Y, Wang C, Zhong Y, Huang X, Peng L, Shan G, et al. Striking life events associated with primary breast cancer susceptibility in women: A meta-analysis study. *J Exp Clin Cancer Res* 2013; 32: 53
38. Lee HE, Lee J, Jang TW, Kim IA, Park J, Song J. The relationship between night work and breast cancer. *Ann Occup Environ Med* 2018; 30: 11
39. Heikkila K, Nyberg ST, Theorell T, Fransson EI, Alfredsson L, Bjorner JB, et al. Work stress and risk of cancer: Meta-analysis of 5700 incident cancer events in 116,000 european men and women. *BMJ* 2013; 346: f165
40. Schoemaker MJ, Jones ME, Wright LB, Griffin J, McFadden E, Ashworth A, et al. Psychological stress, adverse life events and breast cancer incidence: A cohort investigation in 106,000 women in the united kingdom. *Breast Cancer Res* 2016; 18: 72

41. Kamdar BB, Tergas AI, Mateen FJ, Bhayani NH, Oh J. Night-shift work and risk of breast cancer: A systematic review and meta-analysis. *Breast Cancer Res Treat* 2013; 138: 291–301
42. Travis RC, Balkwill A, Fensom GK, Appleby PN, Reeves GK, Wang XS, et al. Night shift work and breast cancer incidence: Three prospective studies and meta-analysis of published studies. *J Natl Cancer Inst* 2016; 108
43. Collaborative Group on Hormonal Factors in Breast C: Breast cancer and breastfeeding: Collaborative reanalysis of individual data from 47 epidemiological studies in 30 countries, including 50302 women with breast cancer and 96973 women without the disease. *Lancet* 2002; 360: 187–195
44. Gierisch JM, Coeytaux RR, Urrutia RP, Havrilesky LJ, Moorman PG, Lowery WJ, et al. Oral contraceptive use and risk of breast, cervical, colorectal, and endometrial cancers: A systematic review. *Cancer Epidemiol Biomarkers Prev* 2013; 22: 1931–1943
45. Cibula D, Gompel A, Mueck AO, La Vecchia C, Hannaford PC, Skouby SO, et al. Hormonal contraception and risk of cancer. *Hum Reprod Update* 2010; 16: 631–650
46. Morch LS, Skovlund CW, Hannaford PC, Iversen L, Fielding S, Lidegaard O. Contemporary hormonal contraception and the risk of breast cancer. *N Engl J Med* 2017; 377: 2228–2239
47. Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrel-releasing intrauterine system in finland. *Obstet Gynecol* 2014; 124: 292–299
48. Jareid M, Thalabard JC, Aarflot M, Bovelstad HM, Lund E, Braaten T. Levonorgestrel-releasing intrauterine system use is associated with a decreased risk of ovarian and endometrial cancer, without increased risk of breast cancer. Results from the nowac study. *Gynecol Oncol* 2018
49. Michels KA, Pfeiffer RM, Brinton LA, Trabert B. Modification of the associations between duration of oral contraceptive use and ovarian, endometrial, breast, and colorectal cancers. *JAMA Oncol* 2018; 4: 516–521
50. Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: The women's health initiative randomized trials. *JAMA* 2017; 318: 927–938
51. Chlebowski RT, Anderson GL: Menopausal hormone therapy and breast cancer mortality: Clinical implications. *Ther Adv Drug Saf* 2015; 6: 45–56
52. Collaborative Group on Hormonal Factors in Breast C: Type and timing of menopausal hormone therapy and breast cancer risk: Individual participant meta-analysis of the worldwide epidemiological evidence. *Lancet* 2019; 394: 1159–1168
53. Postmenopausale Hormontherapie: Bedarf es einer erneuten Trendwende?
<https://www.aerzteblatt.de/nachrichten/83455/postmenopausale-hormontherapie-bedarf-es-einer-erneuten-trendwende>, *Deutsches Ärzteblatt*
54. Colditz GA, Bohlke K, Berkey CS. Breast cancer risk accumulation starts early: Prevention must also. *Breast Cancer Res Treat* 2014; 145: 567–579
55. Collaborative Group on Hormonal Factors in Breast C: Menarche, menopause, and breast cancer risk: Individual participant meta-analysis, including 118 964 women with breast cancer from 117 epidemiological studies. *Lancet Oncol* 2012; 13: 1141–1151
56. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Früherkennung, Diagnose, Therapie und Nachsorge des Mammakarzinoms, Version 4.0, 2017 AWMF Registernummer: 032-045ol, <http://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/>
57. Teras LR, Patel AV, Wang M, Yaun SS, Anderson K, Brathwaite R, et al. Sustained weight loss and risk of breast cancer in women ≥ 50 years: A pooled analysis of prospective data. *J Natl Cancer Inst* 2019
58. Cifu G, Arem H. Adherence to lifestyle-related cancer prevention guidelines and breast cancer incidence and mortality. *Ann Epidemiol* 2018; 28: 767–773 e761
59. Lavalette C, Adjibade M, Srour B, Sellem L, Fiolet T, Hercberg S, et al. Cancer-specific and general nutritional scores and cancer risk: Results from the prospective nutrinet-sante cohort. *Cancer Res* 2018; 78: 4427–4435